Literature DB >> 9380403

HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer.

C C Benz1, R C O'Hagan, B Richter, G K Scott, C H Chang, X Xiong, K Chew, B M Ljung, S Edgerton, A Thor, J A Hassell.   

Abstract

HER2/Neu is overexpressed in 25-30% of all human breast cancers as a result of both gene amplification and enhanced transcription. Transcriptional upregulation of HER2/neu leads to a 6-8-fold increased abundance of its mRNA per gene copy and likely results from the elevated activity of transcription factors acting on the HER2/neu promoter. Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neu-overexpressing human breast tumor samples. Analyses to uncover the molecular basis for elevated PEA3 transcripts in HER2/Neu-positive breast tumors revealed that the HER2/Neu receptor tyrosine kinase initiated an intracellular signaling cascade resulting in increased PEA3 transcriptional activity; transcriptionally-activated PEA3 stimulated HER2/neu and PEA3 gene transcription by binding to sites in the promoters of these genes. PEA3 also activates transcription of genes encoding matrix-degrading proteinases, enzymes required for tumor cell migration and invasion. These findings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins affecting its regulation are appropriate therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9380403     DOI: 10.1038/sj.onc.1201331

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Male sexual dysfunction in mice bearing targeted mutant alleles of the PEA3 ets gene.

Authors:  M A Laing; S Coonrod; B T Hinton; J W Downie; R Tozer; M A Rudnicki; J A Hassell
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

Review 3.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

Review 4.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

Review 5.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

6.  Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy.

Authors:  Guler Yavas; Esin Celik; Cagdas Yavas; Cagdas Elsurer; Rengin Elsurer Afsar
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

Review 7.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

8.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1.

Authors:  Nikhil Tyagi; Sachin K Deshmukh; Sanjeev K Srivastava; Shafquat Azim; Aamir Ahmad; Ahmed Al-Ghadhban; Ajay P Singh; James E Carter; Bin Wang; Seema Singh
Journal:  Mol Cancer Res       Date:  2017-11-08       Impact factor: 5.852

10.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.